2017
Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression
Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, Tu PC, Bai YM, Cheng CM, Krystal JH. Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression. Neuropsychopharmacology 2017, 42: 2482-2492. PMID: 28492279, PMCID: PMC5686503, DOI: 10.1038/npp.2017.94.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntidepressive AgentsAsian PeopleBlood PressureBrain-Derived Neurotrophic FactorDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantDose-Response Relationship, DrugDouble-Blind MethodFemaleHeart RateHumansKetamineMaleMiddle AgedPolymorphism, GeneticPsychiatric Status Rating ScalesTaiwanTreatment OutcomeConceptsTreatment-resistant depressionHamilton Depression Rating ScaleAntidepressant effectsKetamine effectsBDNF genotypeBrain-derived neurotrophic factor (BDNF) genotypeChinese populationDose-related efficacyPlacebo-controlled trialSignificant dose-related effectsDepression Rating ScaleNeurotrophic factor genotypeDose-related effectsSingle ketamine infusionMost patientsKetamine infusionTaiwanese patientsAdjunctive ketamineResponder analysisBDNF geneS-ketamineKetamine levelsPatientsMet alleleRating Scale
2014
In Vivo Ketamine-Induced Changes in [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5
DeLorenzo C, DellaGioia N, Bloch M, Sanacora G, Nabulsi N, Abdallah C, Yang J, Wen R, Mann JJ, Krystal JH, Parsey RV, Carson RE, Esterlis I. In Vivo Ketamine-Induced Changes in [11C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5. Biological Psychiatry 2014, 77: 266-275. PMID: 25156701, PMCID: PMC4277907, DOI: 10.1016/j.biopsych.2014.06.024.Peer-Reviewed Original ResearchConceptsSubtype 5Ketamine administrationPET scansMetabotropic glutamate receptor subtype 5Prefrontal cortexAspartate glutamate receptor antagonistIntravenous ketamine administrationKetamine-induced effectsPositron emission tomography (PET) ligandGlutamate receptor antagonistsVolume of distributionMedial prefrontal cortexNegative allosteric modulatorsKetamine initiationGlutamate releaseDorsal putamenKetamine responseSubanesthetic dosesOrbital prefrontal cortexReceptor antagonistAcute effectsBolus injectionDorsal caudateArterial bloodScan 1
2011
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS
Valentine GW, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH, Sanacora G. The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. Psychiatry Research 2011, 191: 122-127. PMID: 21232924, PMCID: PMC3061550, DOI: 10.1016/j.pscychresns.2010.10.009.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive AgentsBlood PressureDepressive Disorder, MajorDissociative DisordersFemaleGamma-Aminobutyric AcidGlutamic AcidHeart RateHumansKetamineMagnetic Resonance SpectroscopyMaleMiddle AgedOccipital LobeProtonsPsychiatric Status Rating ScalesPsychometricsRetrospective StudiesSingle-Blind MethodStatistics as TopicTime FactorsYoung AdultConceptsMajor depressive disorderAntidepressant effectsAntidepressant actionNeurotransmitter contentNMDA receptor antagonist ketamineProton magnetic resonance spectroscopy methodConventional antidepressant treatmentKetamine's antidepressant actionSingle intravenous doseSingle-blind conditionsAntidepressant treatmentChronic treatmentKetamine infusionIntravenous dosePharmacodynamic basisDepressive disorderAcute actionsMRS scansOccipital cortexDepressive symptomsDepression scoresRating ScaleBaseline measuresInfusionKetamine
2010
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects
Hallak JE, Dursun SM, Bosi DC, de Macedo LR, Machado-de-Sousa JP, Abrão J, Crippa JA, McGuire P, Krystal JH, Baker GB, Zuardi AW. The interplay of cannabinoid and NMDA glutamate receptor systems in humans: Preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2010, 35: 198-202. PMID: 21062637, DOI: 10.1016/j.pnpbp.2010.11.002.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleHealthy human subjectsGlutamate receptor systemMale healthy volunteersNMDA receptor antagonistEffects of ketamineTreatment of schizophreniaPsychiatric Rating ScaleHuman subjectsWeak partial agonistNon-significant trendKetamine administrationReceptor antagonistEndocannabinoid systemHealthy volunteersPartial agonistActivation subscalePsychiatric conditionsKetamineRandomized orderReceptor systemBehavioral effectsRating ScaleCannabidiolPreliminary evidence
2002
Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients
Stine SM, Southwick SM, Petrakis IL, Kosten TR, Charney DS, Krystal JH. Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biological Psychiatry 2002, 51: 642-651. PMID: 11955464, DOI: 10.1016/s0006-3223(01)01292-6.Peer-Reviewed Original ResearchConceptsOpioid-dependent patientsBlood pressureMethadone patientsOpioid dependenceHPA axis perturbationsPlacebo-controlled studyDiastolic blood pressureSystolic blood pressureMethadone-maintained patientsSymptom scale scoresSynaptic noradrenalineOpioid withdrawalPostsynaptic effectsMHPG levelsAbstinence symptomsAdrenal axisOpioid drugsYohimbine effectNoradrenergic regulationHealthy volunteersHeart ratePhysiologic measuresPatientsCortisol levelsScale score
2001
Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men: Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel Antagonists
Krupitsky E, Burakov A, Romanova T, Grinenko N, Grinenko A, Fletcher J, Petrakis I, Krystal J. Attenuation of Ketamine Effects by Nimodipine Pretreatment in Recovering Ethanol Dependent Men: Psychopharmacologic Implications of the Interaction of NMDA and L-Type Calcium Channel Antagonists. Neuropsychopharmacology 2001, 25: 936-947. PMID: 11750186, DOI: 10.1016/s0893-133x(01)00346-3.Peer-Reviewed Original ResearchConceptsVoltage-sensitive calcium channelsL-type voltage-sensitive calcium channelsKetamine effectsStimulant effectsCalcium channelsDouble-blind placebo-controlled studyN-methyl-D-aspartate (NMDA) glutamate receptorsL-type calcium channel antagonistL-type VSCC antagonistBehavioral effectsTransient behavioral effectsPlacebo-controlled studyCalcium channel antagonistsImproved memory functionInteraction of NMDAAspects of schizophreniaNimodipine pretreatmentVSCC antagonistsVerbal fluency impairmentPatient groupKetamine responseChannel antagonistsNMDA antagonistsNMDA receptorsEthanol intoxication
1995
Noradrenergic response to acute ethanol administration in heathly subjects: comparison with intravenous yohimbine
McDougle C, Price L, Heninger G, Krystal J, Charney D. Noradrenergic response to acute ethanol administration in heathly subjects: comparison with intravenous yohimbine. Psychopharmacology 1995, 118: 127-135. PMID: 7617798, DOI: 10.1007/bf02245830.Peer-Reviewed Original ResearchConceptsAcute ethanol administrationEthanol administrationPlasma MHPGIntravenous yohimbineBlood pressureNE turnoverSystolic blood pressureAlpha2-adrenergic receptorsPlacebo-controlled designBlood pressure measurementsEthanol-induced increaseHealthy human subjectsClear additive effectSubjective measuresNE metabolismNoradrenergic responsesNorepinephrine metaboliteCombined administrationMHPG responsePlasma levelsPharmacokinetic effectsOral administrationIntravenous administrationAnxiogenic effectsEthanol intoxicationOpiate Dependence and Withdrawal: Preliminary Assessment Using Single Photon Emission Computerized Tomography (SPECT)
Krystal J, Woods S, Kosten T, Rosen M, Seibyl J, Van Dyck C, Price L, Zubal I, Hoffer P, Charney D. Opiate Dependence and Withdrawal: Preliminary Assessment Using Single Photon Emission Computerized Tomography (SPECT). The American Journal Of Drug And Alcohol Abuse 1995, 21: 47-63. PMID: 7762544, DOI: 10.3109/00952999509095229.Peer-Reviewed Original ResearchConceptsRegional brain functionOpiate withdrawal signsSingle Photon Emission Computerized TomographyHealthy subjectsNaloxone administrationOpiate withdrawalOpiate dependenceBrain functionParietal cortexHexamethylpropyleneamine oximeWithdrawal signsNaloxone effectChronic opiate dependencePlacebo-controlled studyRegional alterationsComparison of patientsMethadone-maintained patientsRegional cerebral perfusionPhoton Emission Computerized TomographyOpiate-dependent patientsRight temporal cortexRight parietal cortexFunctional brain imaging technologiesSingle photon emissionEmission computerized tomography
1994
Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms
Krystal JH, Webb E, Cooney N, Kranzler HR, Charney DS. Specificity of Ethanollike Effects Elicited by Serotonergic and Noradrenergic Mechanisms. JAMA Psychiatry 1994, 51: 898-911. PMID: 7944878, DOI: 10.1001/archpsyc.1994.03950110058008.Peer-Reviewed Original ResearchConceptsVisual analog scaleAnalog scaleScale scoreVisual analog scale scoreYohimbine hydrochlorideAnalog scale scoreDouble-blind conditionsEffect of mCPPReceptor partial agonistEffects of ethanolNoradrenergic mechanismsIntravenous infusionPlasma levelsSerotonergic systemNoradrenergic systemPlaceboDiscriminative propertiesMale inpatientsYohimbinePlasma prolactinCortisol levelsPartial agonistSerotonergic contributionAlcohol dependenceDays of testingSubanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses
Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB, Charney DS. Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses. JAMA Psychiatry 1994, 51: 199-214. PMID: 8122957, DOI: 10.1001/archpsyc.1994.03950030035004.Peer-Reviewed Original ResearchMeSH KeywordsAdultBlood PressureCognitionDissociative DisordersDose-Response Relationship, DrugDouble-Blind MethodFemaleFrontal LobeHomovanillic AcidHumansHydrocortisoneKetamineMaleMethoxyhydroxyphenylglycolNeuropsychological TestsPerceptionProlactinPsychiatric Status Rating ScalesPsychoses, Substance-InducedPulseReceptors, N-Methyl-D-AspartateSchizophreniaSchizophrenic PsychologyConceptsWisconsin Card Sorting TestCard Sorting TestMini-Mental State ExaminationSorting TestNegative symptomsTests of vigilanceVerbal fluency taskDissociative statesState ExaminationFrontal cortical dysfunctionPsychosis Proneness ScalesClinician-Administered Dissociative States ScaleWord recallImmediate recallVerbal fluencyFluency taskVigilance taskCognitive deficitsCognitive functionRecallState scaleBrief Psychiatric Rating ScaleCortical dysfunctionTest dayPsychiatric Rating Scale
1992
Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients
Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatrica Scandinavica 1992, 86: 273-282. PMID: 1333719, DOI: 10.1111/j.1600-0447.1992.tb03266.x.Peer-Reviewed Original ResearchConceptsPanic disorder patientsDisorder patientsPanic disorderIntravenous yohimbineHealthy subjectsYohimbine-induced panic attacksClonidine-induced decreaseYohimbine-induced increasesGrowth hormone responseNeuronal dysregulationCardiovascular effectsPlasma MHPGPatientsPlasma 3Hormone responseNeuronal functionPanic attacksClonidineHuman dataDisordersYohimbineHuman anxietySubgroupsFear statesFunctional regulationDose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine
Krystal J, McDougle C, Woods S, Price L, Heninger G, Charney D. Dose-response relationship for oral idazoxan effects in healthy human subjects: comparison with oral yohimbine. Psychopharmacology 1992, 108: 313-319. PMID: 1355923, DOI: 10.1007/bf02245117.Peer-Reviewed Original ResearchConceptsHealthy subjectsDiastolic blood pressureΑ2-adrenergic receptorsSymptom scale scoresHealthy human subjectsDose-response relationshipIdazoxan doseBlood pressureOral yohimbineNorepinephrine metabolitePlasma levelsMedication effectsOral administrationPlasma MHPGPhysiologic indicesNeuroendocrine responsesΑ2 antagonistAdrenergic receptorsCortisol levelsScale scorePlasma cortisolYohimbineIdazoxanAnxiety statesReceptor specificity
1989
Use of Yohimbine to Counteract Nortriptyline-Induced Orthostatic Hypotension
SEIBYL J, KRYSTAL J, PRICE L, CHARNEY D. Use of Yohimbine to Counteract Nortriptyline-Induced Orthostatic Hypotension. Journal Of Clinical Psychopharmacology 1989, 9: 67-68. PMID: 2708559, DOI: 10.1097/00004714-198902000-00026.Peer-Reviewed Original Research